Meeting
2011 ASCO Annual Meeting
Association of germ-line SNPs with overall survival (OS) in pazopanib-treated patients (Pts) with advanced renal cell carcinoma (RCC).
Authors
C. Xu
GlaxoSmithKline, Harlow, United Kingdom
C. Xu , N. Bing , H. A. Ball , C. N. Sternberg , I. D. Davis , Z. Xue , L. McCann , K. King , J. C. Whittaker , C. F. Spraggs , V. E. Mooser , L. N. Pandite
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4558)
Abstract #
4558
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Pharmacogenetics revisits bevacizumab in breast cancer patients: An ancillary analysis of the UCBG trial COMET— A French multicentric prospective study from R&D UNICANCER.
First Author: Gerard A. Milano
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.
First Author: Arielle G. Bensimon
Poster
2018 Genitourinary Cancers Symposium
Clinical validation of single nucleotide polymorphisms (SNPs) as predictive biomarkers in localized and metastatic renal cell cancer (RCC).
First Author: Carmen Garrigos
Poster
2018 Genitourinary Cancers Symposium
Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).
First Author: Martin Henner Voss